IMMUNOME INC (IMNM) — insider trading
Health Care · NASDAQ
IMMUNOME INC (IMNM) has 60 reported SEC Form 4 insider transactions in our data, including 4 open-market purchases and 21 open-market sales among the most recent 60 (latest 2026-09-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Higgins Jack | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 18,000 | — | $0 | Form 4 |
| 2026-09-11 | Higgins Jack | Officer (Chief Scientific Officer) | Bona fide gift | 8,800 | — | $0 | Form 4 |
| 2026-09-11 | Higgins Jack | Officer (Chief Scientific Officer) | Open-market sale | 13,200 | $25.32 | $334.2K | Form 4 |
| 2026-09-11 | Higgins Jack | Officer (Chief Scientific Officer) | Option exercise / conversion | 18,000 | $1.35 | $24.3K | Form 4 |
| 2026-08-12 | Barchas Isaac | Director | Open-market sale | 11,048 | $27.25 | $301.1K | Form 4 |
| 2026-08-11 | Barchas Isaac | Director | Open-market sale | 62,291 | $26.23 | $1.63M | Form 4 |
| 2026-08-10 | Barchas Isaac | Director | Open-market sale | 10,125 | $26.07 | $264.0K | Form 4 |
| 2026-08-07 | Barchas Isaac | Director | Open-market sale | 15,248 | $26.06 | $397.4K | Form 4 |
| 2026-08-06 | Barchas Isaac | Director | Open-market sale | 20,840 | $26.06 | $543.1K | Form 4 |
| 2026-08-04 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Option exercise / conversion (derivative) | 40,250 | — | $0 | Form 4 |
| 2026-08-04 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Option exercise / conversion (derivative) | 50,366 | — | $0 | Form 4 |
| 2026-08-04 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Open-market sale | 90,616 | $25.09 | $2.27M | Form 4 |
| 2026-08-04 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Option exercise / conversion | 40,250 | $10.60 | $426.6K | Form 4 |
| 2026-08-04 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Option exercise / conversion | 50,366 | $12.92 | $650.7K | Form 4 |
| 2026-07-23 | SIEGALL CLAY B | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 360,000 | — | $0 | Form 4 |
| 2026-07-23 | SIEGALL CLAY B | Director, Officer (President and CEO) | Grant / award / vesting | 180,000 | — | $0 | Form 4 |
| 2026-07-23 | Lechleider Robert | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 108,000 | — | $0 | Form 4 |
| 2026-07-23 | Lechleider Robert | Officer (Chief Medical Officer) | Grant / award / vesting | 54,000 | — | $0 | Form 4 |
| 2026-07-23 | Rosett Max | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 94,500 | — | $0 | Form 4 |
| 2026-07-23 | Rosett Max | Officer (Chief Financial Officer) | Grant / award / vesting | 47,250 | — | $0 | Form 4 |
| 2026-07-23 | Higgins Jack | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 76,500 | — | $0 | Form 4 |
| 2026-07-23 | Higgins Jack | Officer (Chief Scientific Officer) | Grant / award / vesting | 38,250 | — | $0 | Form 4 |
| 2026-07-23 | Stoneman Sandra G. | Officer (CHIEF LEGAL OFFICER & GC) | Grant / award / vesting (derivative) | 76,500 | — | $0 | Form 4 |
| 2026-07-23 | Stoneman Sandra G. | Officer (CHIEF LEGAL OFFICER & GC) | Grant / award / vesting | 38,250 | — | $0 | Form 4 |
| 2026-07-23 | Tsai Philip | Officer (Chief Technical Officer) | Grant / award / vesting (derivative) | 76,500 | — | $0 | Form 4 |
| 2026-07-23 | Tsai Philip | Officer (Chief Technical Officer) | Grant / award / vesting | 38,250 | — | $0 | Form 4 |
| 2026-07-23 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Grant / award / vesting (derivative) | 62,500 | — | $0 | Form 4 |
| 2026-07-23 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Grant / award / vesting | 31,250 | — | $0 | Form 4 |
| 2026-07-07 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Option exercise / conversion (derivative) | 1,092 | — | $0 | Form 4 |
| 2026-07-07 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Open-market sale | 1,092 | $25.00 | $27.3K | Form 4 |
| 2026-07-07 | Horn Kinney | Officer (CHIEF BUSINESS OFFICER) | Option exercise / conversion | 1,092 | $12.92 | $14.1K | Form 4 |
| 2026-07-07 | Barchas Isaac | Director | Open-market sale | 16,906 | $24.20 | $409.1K | Form 4 |
| 2026-07-06 | Barchas Isaac | Director | Open-market sale | 83,094 | $24.11 | $2.00M | Form 4 |
| 2026-07-02 | Lechleider Robert | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 55,000 | — | $0 | Form 4 |
| 2026-07-02 | Lechleider Robert | Officer (Chief Medical Officer) | Open-market sale | 16,072 | $23.44 | $376.7K | Form 4 |
| 2026-07-02 | Lechleider Robert | Officer (Chief Medical Officer) | Open-market sale | 16,214 | $22.76 | $369.0K | Form 4 |
| 2026-07-02 | Lechleider Robert | Officer (Chief Medical Officer) | Open-market sale | 22,714 | $21.95 | $498.6K | Form 4 |
| 2026-07-02 | Lechleider Robert | Officer (Chief Medical Officer) | Option exercise / conversion | 55,000 | $8.73 | $480.1K | Form 4 |
| 2026-07-02 | Barchas Isaac | Director | Open-market sale | 24,335 | $23.33 | $567.7K | Form 4 |
| 2026-07-02 | Barchas Isaac | Director | Open-market sale | 75,665 | $22.35 | $1.69M | Form 4 |
| 2026-06-30 | Barchas Isaac | Director | Open-market sale | 101,050 | $21.12 | $2.13M | Form 4 |
| 2026-06-25 | Lechleider Robert | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 55,000 | — | $0 | Form 4 |
| 2026-06-25 | Lechleider Robert | Officer (Chief Medical Officer) | Open-market sale | 14,420 | $20.66 | $297.9K | Form 4 |
| 2026-06-25 | Lechleider Robert | Officer (Chief Medical Officer) | Open-market sale | 40,580 | $19.56 | $793.7K | Form 4 |
| 2026-06-25 | Lechleider Robert | Officer (Chief Medical Officer) | Option exercise / conversion | 55,000 | $8.73 | $480.1K | Form 4 |
| 2026-06-15 | Rosett Max | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 60,000 | — | $0 | Form 4 |
| 2026-06-15 | Rosett Max | Officer (Chief Financial Officer) | Open-market sale | 60,000 | $18.23 | $1.09M | Form 4 |
| 2026-06-15 | Rosett Max | Officer (Chief Financial Officer) | Option exercise / conversion | 60,000 | $1.05 | $63.0K | Form 4 |
| 2026-06-10 | SCHAFER CAROL | Director | Grant / award / vesting (derivative) | 9,897 | — | $0 | Form 4 |
| 2026-06-10 | Barchas Isaac | Director | Grant / award / vesting (derivative) | 9,897 | — | $0 | Form 4 |
| 2026-06-10 | Boylan James P | Director | Grant / award / vesting (derivative) | 9,897 | — | $0 | Form 4 |
| 2026-06-10 | BIENAIME JEAN JACQUES | Director | Grant / award / vesting (derivative) | 9,897 | — | $0 | Form 4 |
| 2026-06-10 | WAGENHEIM PHILIP | Director | Grant / award / vesting (derivative) | 9,897 | — | $0 | Form 4 |
| 2026-06-10 | SWAIN SANDRA M | Director | Grant / award / vesting (derivative) | 9,897 | — | $0 | Form 4 |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 1,000 | $19.27 | $19.3K | Form 4 |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 3,500 | $19.46 | $68.1K | Form 4 |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 6,000 | $19.48 | $116.9K | Form 4 |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Open-market sale | 10,000 | $19.41 | $194.1K | Form 4 |
| 2026-06-05 | BIENAIME JEAN JACQUES | Director | Open-market sale | 500 | $19.44 | $9.7K | Form 4 |
| 2026-05-15 | BIENAIME JEAN JACQUES | Director | Open-market purchase | 5,000 | $20.70 | $103.5K | Form 4 |
Ask the chat about IMNM's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: IMMUNOME INC (IMNM).
Last updated 2026-09-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.